Objective of the study: To evaluate the quality of life (QL) for the patients presenting with inflammatory intestinal disorders (IID) taking into consideration their age and gender as well as dynamics of the disease under the influence of biological and standard therapy. Materials and methods. A total of 58 patients with IID were interviewed with the use of the SF-36 questionnaire including 23 (39.6%) ones suffering from Crohn’s disease and 35 (60.4%) with ulcerative colitis. Mild symptoms of inflammatory intestinal disorders were documented in 3 (5.2%) patients, moderately severe symptoms in 34 (58.6%), and severe symptoms in 21 (36.2%). Extraintestinal manifestation took place in 14 (24.1%) patients. The patients included in the study were 27 (46.6%) men and 31 (53.4%) women. The mean age of the patients was 38.2±1.2 years. The group of the patients aged from 18 to 24 years was comprised of 14 (24.1%) subjects, the group of the patients at the age from 25 to 44 years consisted of 29 (50.0%) subjects, and group 3 of the patients aged 45 and more years included 15 (25.9%) subjects. Thirty one patients were interviewed again one year after the standard treatment with the use of preparations of 5-aminosalycilic acid and glucocorticoids, 27 patients were questioned repeatedly after infliximab (INFL) therapy. Results. Prior to the onset of the study, all the patients exhibited subnormal QL characteristics based on all the scales of the SF-36 questionnaire including negative changes in the psychoemotional and social spheres. The treatment induced a positive tendency toward the improvement of all parameters of the quality of life that was especially well apparent in the patients given INFL therapy. These changes were shown to be related to the patients’ gender. It is concluded that the management of the patients presenting with inflammatory intestinal disorders requires participation not only of gastroenterologists but also of psychologists and psychotherapists.